Rational considerations about development of live attenuated Yersinia pestis vaccines

Wei Sun, Roy Curtiss

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.

Original languageEnglish (US)
Pages (from-to)878-886
Number of pages9
JournalCurrent Pharmaceutical Biotechnology
Volume14
Issue number10
DOIs
StatePublished - 2013

Fingerprint

Yersinia pestis
Plague
Subunit Vaccines
Vaccines
Plague Vaccine
Safety
Attenuated Vaccines
USSR
Research
Cellular Immunity
Antibody Formation
Virulence

Keywords

  • Immune response
  • Live attenuated Y. pestis vaccines
  • Plague
  • Yersinia pestis

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Biotechnology

Cite this

Rational considerations about development of live attenuated Yersinia pestis vaccines. / Sun, Wei; Curtiss, Roy.

In: Current Pharmaceutical Biotechnology, Vol. 14, No. 10, 2013, p. 878-886.

Research output: Contribution to journalArticle

@article{435eee91f1e746a7acb21d083e331c09,
title = "Rational considerations about development of live attenuated Yersinia pestis vaccines",
abstract = "The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.",
keywords = "Immune response, Live attenuated Y. pestis vaccines, Plague, Yersinia pestis",
author = "Wei Sun and Roy Curtiss",
year = "2013",
doi = "10.2174/1389201014666131226122243",
language = "English (US)",
volume = "14",
pages = "878--886",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Rational considerations about development of live attenuated Yersinia pestis vaccines

AU - Sun, Wei

AU - Curtiss, Roy

PY - 2013

Y1 - 2013

N2 - The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.

AB - The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.

KW - Immune response

KW - Live attenuated Y. pestis vaccines

KW - Plague

KW - Yersinia pestis

UR - http://www.scopus.com/inward/record.url?scp=84896738199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896738199&partnerID=8YFLogxK

U2 - 10.2174/1389201014666131226122243

DO - 10.2174/1389201014666131226122243

M3 - Article

C2 - 24372254

AN - SCOPUS:84896738199

VL - 14

SP - 878

EP - 886

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 10

ER -